knowledge -WSS

knowledge

author：focus 2025-09-03 05:33:32 - browse：8992

Fran van Delft for Galapagos

Seeking to differentiate itself from other makers of CAR-T cancer therapies, Galapagos NV on Wednesday announced it had struck a deal with Blood Centers of America to open up dozens of manufacturing sites for its cell-based medicines around the U.S.

Galapagos said it will rely on the partnership, the financial terms of which were not disclosed, as it moves its CAR-Ts for different cancers into pivotal studies and could also help launch those medicines should they win approval. The Belgian company framed the collaboration as one that could help overcome the limitations that have held back access to existing CAR-T therapies from other companies.

CAR-Ts have proven to be potent treatments for certain cancers, but they are complicated medicines to make. Immune cells have to be removed from a patient, shipped to specialty sites, where they’re engineered with cancer-killing abilities, and then returned to the hospital for infusion back into patients. The process, which can take weeks if not months, has put a crunch on the number of patients companies and hospitals are able to treat.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum
Next article： It was time to plan for my old age. If only I could stop crying

leisure time

WSS

Sage considers ways to reduce costs following FDA rejection

Lack of health data on LGBTQ+ people has serious consequences

Restaurant meals are packed with calories, and we still keep eating them

For AI in health care standards, federal regulators join with industry group

Immune cells and nerve overgrowth may explain recurring UTI pain

Many breast cancer patients receive more radiation than needed

focus

knowledge

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

leisure time

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Pregnant women don't need prenatal multivitamins, study concludes

At least 13 dead in Texas as scorching temps continue

Sweden knocks USA out of World Cup in penalty kicks

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

Medicare drug price negotiation continues, as pharma counteroffers

Alkermes shareholders re

Ancient Greek ideas underpin modern concepts of pregnancy

Moonlake's readout produced a cash windfall. Risks remain

A fugitive mob suspect in Greece is betrayed by his passion for hometown Naples soccer champions

hotspot

Google's generative AI to analyze medical images — and talk to docs

Election results set back Medicaid expansion plans

Sweden knocks USA out of World Cup in penalty kicks

Change Healthcare cyberattack affects 25% of CVS/Aetna insurance claims

Families look for replacement for GSK asthma drug Flovent

Many breast cancer patients receive more radiation than needed

leisure time

hotspot

entertainment

entertainment